Sophia Tsabouri, Ioannis Georgiou, Afroditi Katsaraki, Kostantinos Lambros Bourantas
{"title":"慢性淋巴细胞白血病谷胱甘肽硫转移酶M1和T1基因型。","authors":"Sophia Tsabouri, Ioannis Georgiou, Afroditi Katsaraki, Kostantinos Lambros Bourantas","doi":"10.1038/sj.thj.6200555","DOIUrl":null,"url":null,"abstract":"<p><p>Glutathione sulfur transferases (GSTs) is a group of enzymes involved in the detoxification process of carcinogens and other substances. The genes encoding isoenzymes M1 and T1 are polymorphic in humans and the phenotypic absence of enzyme activity (null genotype) may have an effect on the risk of chronic lymphoblastic leukemia (CLL). Our purpose was to examine whether the GSTM1 and GSTT1 homozygous null genotypes altered the risk of CLL. DNA was extracted from the peripheral blood of 27 patients with CLL and 147 cancer-free controls; both groups originated from a defined population (residents of the Ioannina region, northwestern Greece) and were similar with regard to mean age, race and sex; GSTM1 and GSTT1 were simultaneously analyzed by a multiplex polymerase chain reaction (PCR) method and Fisher's exact test was used for comparisons between the two groups. A significantly increased incidence of the GSTM1 null genotype was found in the group of patients compared to the controls (74.07 versus 34.69%, P = 0.0002). Additionally, the incidence of the GSTT1 null genotype was comparable in patients and controls (25.92 versus 10.20%, P = 0.05). The frequency of the combined GSTM1 null/T1 null genotype was significantly different between patients and controls (14.81 versus 2.04%, P = 0.012). However, there was no relationship between the advanced stage of the disease and the GSTs status. Individuals with the GSTM1 and GSTT1 null genotypes may have enhanced susceptibility to CLL.</p>","PeriodicalId":22486,"journal":{"name":"The hematology journal : the official journal of the European Haematology Association","volume":"5 6","pages":"500-4"},"PeriodicalIF":0.0000,"publicationDate":"2004-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/sj.thj.6200555","citationCount":"0","resultStr":"{\"title\":\"Glutathione sulfur transferase M1 and T1 genotypes in chronic lymphoblastic leukemia.\",\"authors\":\"Sophia Tsabouri, Ioannis Georgiou, Afroditi Katsaraki, Kostantinos Lambros Bourantas\",\"doi\":\"10.1038/sj.thj.6200555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glutathione sulfur transferases (GSTs) is a group of enzymes involved in the detoxification process of carcinogens and other substances. The genes encoding isoenzymes M1 and T1 are polymorphic in humans and the phenotypic absence of enzyme activity (null genotype) may have an effect on the risk of chronic lymphoblastic leukemia (CLL). Our purpose was to examine whether the GSTM1 and GSTT1 homozygous null genotypes altered the risk of CLL. DNA was extracted from the peripheral blood of 27 patients with CLL and 147 cancer-free controls; both groups originated from a defined population (residents of the Ioannina region, northwestern Greece) and were similar with regard to mean age, race and sex; GSTM1 and GSTT1 were simultaneously analyzed by a multiplex polymerase chain reaction (PCR) method and Fisher's exact test was used for comparisons between the two groups. A significantly increased incidence of the GSTM1 null genotype was found in the group of patients compared to the controls (74.07 versus 34.69%, P = 0.0002). Additionally, the incidence of the GSTT1 null genotype was comparable in patients and controls (25.92 versus 10.20%, P = 0.05). The frequency of the combined GSTM1 null/T1 null genotype was significantly different between patients and controls (14.81 versus 2.04%, P = 0.012). However, there was no relationship between the advanced stage of the disease and the GSTs status. Individuals with the GSTM1 and GSTT1 null genotypes may have enhanced susceptibility to CLL.</p>\",\"PeriodicalId\":22486,\"journal\":{\"name\":\"The hematology journal : the official journal of the European Haematology Association\",\"volume\":\"5 6\",\"pages\":\"500-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1038/sj.thj.6200555\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The hematology journal : the official journal of the European Haematology Association\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/sj.thj.6200555\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The hematology journal : the official journal of the European Haematology Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/sj.thj.6200555","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
谷胱甘肽硫转移酶(GSTs)是一组参与致癌物和其他物质解毒过程的酶。编码同工酶M1和T1的基因在人类中是多态性的,酶活性的表型缺失(零基因型)可能对慢性淋巴细胞白血病(CLL)的风险有影响。我们的目的是检查GSTM1和GSTT1纯合零基因型是否改变了CLL的风险。从27例CLL患者和147例无癌对照者的外周血中提取DNA;这两个群体都来自一个确定的人群(希腊西北部约阿尼纳地区的居民),并且在平均年龄、种族和性别方面相似;采用多重聚合酶链反应(PCR)方法对GSTM1和GSTT1同时进行分析,两组间比较采用Fisher精确检验。与对照组相比,患者组GSTM1零基因型的发生率显著增加(74.07 vs 34.69%, P = 0.0002)。此外,GSTT1零基因型在患者和对照组中的发生率相当(25.92%对10.20%,P = 0.05)。GSTM1 /T1联合零基因型的频率在患者和对照组之间有显著差异(14.81 vs 2.04%, P = 0.012)。然而,疾病的晚期与GSTs状态之间没有关系。具有GSTM1和GSTT1零基因型的个体可能对CLL具有更高的易感性。
Glutathione sulfur transferase M1 and T1 genotypes in chronic lymphoblastic leukemia.
Glutathione sulfur transferases (GSTs) is a group of enzymes involved in the detoxification process of carcinogens and other substances. The genes encoding isoenzymes M1 and T1 are polymorphic in humans and the phenotypic absence of enzyme activity (null genotype) may have an effect on the risk of chronic lymphoblastic leukemia (CLL). Our purpose was to examine whether the GSTM1 and GSTT1 homozygous null genotypes altered the risk of CLL. DNA was extracted from the peripheral blood of 27 patients with CLL and 147 cancer-free controls; both groups originated from a defined population (residents of the Ioannina region, northwestern Greece) and were similar with regard to mean age, race and sex; GSTM1 and GSTT1 were simultaneously analyzed by a multiplex polymerase chain reaction (PCR) method and Fisher's exact test was used for comparisons between the two groups. A significantly increased incidence of the GSTM1 null genotype was found in the group of patients compared to the controls (74.07 versus 34.69%, P = 0.0002). Additionally, the incidence of the GSTT1 null genotype was comparable in patients and controls (25.92 versus 10.20%, P = 0.05). The frequency of the combined GSTM1 null/T1 null genotype was significantly different between patients and controls (14.81 versus 2.04%, P = 0.012). However, there was no relationship between the advanced stage of the disease and the GSTs status. Individuals with the GSTM1 and GSTT1 null genotypes may have enhanced susceptibility to CLL.